Centiva Capital’s Coherus Oncology CHRS Stock Holding History

Centiva Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,300	Closed	-$48.3K	–	1754
2023 Q2	$48.3K	Buy	+11,300	New	+$66.7K	﹤0.01%	1505

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return

Centiva Capital's CHRS Position: Q3 2023 in Review

Centiva Capital sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 11,300 shares — an estimated $48.3K sold.

Centiva Capital first reported a position in CHRS in Q2 2023 and held it in 1 quarter. The position peaked at $48.3K in Q2 2023. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

Centiva Capital reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
Centiva Capital sold 11,300 Coherus Oncology shares in Q3 2023, an estimated $48.3K.
Centiva Capital first reported a position in Coherus Oncology in Q2 2023 and held it in 1 quarter.
Centiva Capital's Coherus Oncology position peaked at $48.3K in Q2 2023.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.